{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Colomer-Castell S"],"funding":["Spanish Ministry of Educatio","Gilead Sciences (Spain)","Instituto de Salud Carlos III","Gilead’s biomedical research","CaixaBank","European Union","Ministerio de Educación y Formación Profesional","Centre for Industrial Technological Development","Ministerio de Ciencia e Innovación","Instituto de Salud Carlos III (ISCIII)","Spanish Ministry of Economy and Business","Plan Estratègic de Recerca i Innovació en Salut (PERIS)"],"pagination":["17185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10743355"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(24)"],"pubmed_abstract":["Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed cons"],"journal":["International journal of molecular sciences"],"pubmed_title":["In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments."],"pmcid":["PMC10743355"],"funding_grant_id":["FPU21/04150","LCF/BQ/DR23/12000020","PI19/00301","DGRIS","GLD21/00006","PID2021-126447OB-I00","PI22/00258","IDI-20200297"],"pubmed_authors":["Vico-Romero J","Campos C","Riveiro-Barciela M","Quer J","Esteban JI","Ibanez-Lligona M","Garcia-Cehic D","Gregori J","Rando-Segura A","Cortese MF","Buti M","Rodriguez-Frias F","Colomer-Castell S","Adombi CM","Tabernero D"],"additional_accession":[]},"is_claimable":false,"name":"In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments.","description":"Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed cons","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-04-26T03:23:35.564Z","creation":"2025-04-05T10:16:35.373Z"},"accession":"S-EPMC10743355","cross_references":{"pubmed":["38139013"],"doi":["10.3390/ijms242417185"]}}